Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MSI-H/dMMR Colorectal Cancer”

90 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 90 results

Testing effectiveness (Phase 2)Looking for participantsNCT07213609
What this trial is testing

Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Who this might be right for
Neoplasms, ColorectalNeoplasms
GlaxoSmithKline 47
Not applicableStudy completedNCT06717763
What this trial is testing

Surgery Following Immune Checkpoint Inhibitions for Controlled Disease in Recurrent or Metastatic dMMR/MSI-H Colorectal Cancer

Who this might be right for
Colorectal Cancer
Sun Yat-sen University 40
Not applicableStudy completedNCT05871567
What this trial is testing

Predictive Value of DNA Mismatch Repair System in Colorectal Cancers

Who this might be right for
MSI-H Colorectal Cancer
University of Campania Luigi Vanvitelli 403
Testing effectiveness (Phase 2)Active Not RecruitingNCT04715633
What this trial is testing

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer

Who this might be right for
Colorectal CancerMicrosatellite Instability High
Sun Yat-sen University 53
Early research (Phase 1)Study completedNCT04357587
What this trial is testing

Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal Cancer

Who this might be right for
Rectal Neoplasms
Case Comprehensive Cancer Center 6
Testing effectiveness (Phase 2)UnknownNCT04866862
What this trial is testing

Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

Who this might be right for
Colorectal Neoplasm
The First Affiliated Hospital with Nanjing Medical University 32
Testing effectiveness (Phase 2)Ended earlyNCT04258111
What this trial is testing

IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Innovent Biologics (Suzhou) Co. Ltd. 4
Testing effectiveness (Phase 2)Looking for participantsNCT06205836
What this trial is testing

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

Who this might be right for
Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 33
Testing effectiveness (Phase 2)Active Not RecruitingNCT06640049
What this trial is testing

Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China

Who this might be right for
Neoplasms, Rectal
GlaxoSmithKline 23
Testing effectiveness (Phase 2)Active Not RecruitingNCT04895722
What this trial is testing

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)

Who this might be right for
Colorectal Cancer
Merck Sharp & Dohme LLC 302
Not applicableNot Yet RecruitingNCT07352280
What this trial is testing

Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer

Who this might be right for
Colo-rectal Cancer (dMMR/MSI-H CRC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 30
Large-scale testing (Phase 3)Looking for participantsNCT06520683
What this trial is testing

Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer

Who this might be right for
Colorectal CancerMicrosatellite Instability High
Sun Yat-sen University 180
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07009145
What this trial is testing

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

Who this might be right for
Unresectable Colorectal CancerMetastatic Colorectal Cancer (CRC)MSI-H/dMMR Colorectal Cancer
Qianfoshan Hospital 22
Early research (Phase 1)Ended earlyNCT04272034
What this trial is testing

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsMSI-H/dMMR TumorsCutaneous Squamous Cell Carcinoma+15 more
Incyte Corporation 105
Testing effectiveness (Phase 2)Looking for participantsNCT04636008
What this trial is testing

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Who this might be right for
Anti-PD-1 AntibodyRadiotherapyRectal Cancer+2 more
West China Hospital 20
Testing effectiveness (Phase 2)Study completedNCT01461148
What this trial is testing

Vaccination Against MSI Colorectal Cancer

Who this might be right for
Colorectal Cancer
Oryx GmbH & Co. KG 22
Early research (Phase 1)Study completedNCT02635672
What this trial is testing

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Who this might be right for
Neoplasms
Vincerx Pharma, Inc. 110
Testing effectiveness (Phase 2)Active Not RecruitingNCT03228667
What this trial is testing

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Who this might be right for
Non-Small Cell Lung CancerSmall Cell Lung CancerUrothelial Carcinoma+10 more
ImmunityBio, Inc. 40
Testing effectiveness (Phase 2)UnknownNCT05429866
What this trial is testing

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Who this might be right for
Breast CancerMelanomaNon Small Cell Lung Cancer+10 more
Jules Bordet Institute 441
Testing effectiveness (Phase 2)Study completedNCT03241173
What this trial is testing

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Who this might be right for
Advanced Malignancies
Incyte Biosciences International Sàrl 52
Load More Results